CNTB

Connect Biopharma is a clinical-stage, one-drug story: its entire value rests on rademikibart, an IL-4R antibody for asthma/COPD, and the 10-K states plainly that 'we currently only have rademikibart in clinical development.' There is no product revenue — the $64.0K reported for FY2025 is a rounding error versus the $26.0M collaboration/milestone revenue booked in FY2024, so the -99.8% 'decline' simply reflects that a one-time collaboration payment did not recur. Every headline ratio built on that revenue (P/S of 2,172x, -86,687% net margin) is therefore meaningless; the only numbers that matter here are burn and runway.

And the burn/runway math is alarming. FY2025 operating cash flow was -$51.2M against just $38.3M of cash and equivalents (itself down 51% YoY). That is well under twelve months of runway at the current pace, and management explicitly guides that losses 'will increase substantially' as R&D expands (R&D already +29.2% to $37.8M). With an accumulated deficit of $400.8M and net loss widening back to $55.5M (from $15.6M in the collaboration-boosted 2024), a dilutive equity raise or new partnership is not a risk — it is a near-certainty within the next few quarters, and it will hit a 56.5M-share base at a depressed $2.46 price.